VX-121/TEZ/D-IVA
Phase 3RecruitingInterest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cystic Fibrosis
Conditions
Cystic Fibrosis
Trial Timeline
Jun 21, 2022 → Jun 30, 2030
NCT ID
NCT05422222About VX-121/TEZ/D-IVA
VX-121/TEZ/D-IVA is a phase 3 stage product being developed by Vertex Pharmaceuticals for Cystic Fibrosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05422222. Target conditions include Cystic Fibrosis.
What happened to similar drugs?
20 of 20 similar drugs in Cystic Fibrosis were approved
Approved (20) Terminated (7) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05444257 | Phase 3 | Active |
| NCT05535959 | Phase 1 | Completed |
| NCT05437120 | Phase 1 | Completed |
| NCT05422222 | Phase 3 | Recruiting |
Competing Products
20 competing products in Cystic Fibrosis